-
OMV-Displayed mRNA Antigens for Personalized Tumor Vaccines
2026-08-15
The reference study developed engineered bacterial outer membrane vesicles (OMV-LL) that rapidly capture sequence-tagged mRNA antigens and promote dendritic-cell delivery, endosomal escape, and cross-presentation. In mouse tumor models, the platform inhibited melanoma, produced complete regression in a subset of colon tumors, and generated durable antitumor memory, while also offering a distinct strategy for personalized vaccine assembly.
-
TECPR1-Mediated Lysosomal Repair Under Energy Stress
2026-08-14
A 2026 Cell Research study identifies TECPR1 as a lysosomal repair factor that senses PI4P-enriched damaged membranes and cooperates with KIF1A to generate membrane tubules. The work connects lysosomal membrane remodeling with survival during glucose deprivation and liver protection in a metabolic dysfunction-associated fatty liver disease model.
-
Capsaicin as a KDM1A/LSD1 Inhibitor
2026-08-14
The reference study identifies Capsaicin, also called (E)-Capsaicin, as a direct, reversible, FAD-competitive inhibitor of lysine-specific demethylase 1A (KDM1A/LSD1). Its cellular data connect KDM1A inhibition with reduced gastric cancer cell migration and invasion through reversal of epithelial–mesenchymal transition, while also defining important limitations for translational interpretation.
-
SIS3: Selective Smad3 Inhibitor for Research
2026-08-13
SIS3 is a selective Smad3 inhibitor that suppresses Smad3 phosphorylation and Smad3–Smad4 signaling without affecting Smad2 phosphorylation, according to product information. Peer-reviewed osteoarthritis research links SIS3 treatment with reduced ADAMTS-5 expression and increased miRNA-140 in rat cartilage models.
-
Regulated Cell Death Mechanisms in Heart Disease
2026-08-13
Konstantinidis, Whelan, and Kitsis integrate evidence showing that apoptosis and necrosis are distinct but interconnected outcomes of shared death-signaling networks in myocardial infarction and heart failure. The review’s main practical contribution is a framework for interpreting regulated necrosis, mitochondrial and endoplasmic-reticulum signaling, ATP loss, and inflammatory injury when designing cardiovascular cell-death experiments.
-
Protease Inhibitor Cocktail: MS-Safe Workflow
2026-08-12
Learn how to use a 50X, AEBSF-free Protease Inhibitor Cocktail to preserve proteins during cell and tissue extraction without compromising mass spectrometry workflows. The guide connects cold-chain handling, pH-aware sample design, optional EDTA supplementation, and troubleshooting to practical proteomics and structural assays.
-
DFCP1 Controls Starvation-Driven ATGL Lipolysis
2026-08-12
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of lipid droplet catabolism that recruits ATGL to droplets during starvation. Its findings connect DFCP1-dependent spatial control of ATGL residence time with reduced lipolysis, providing a mechanistic framework for studying lipid mobilization and associated protein complexes.
-
Lipo3K Transfection Reagent for APOL1 Assays
2026-08-11
Discover how Lipo3K Transfection Reagent can support controlled APOL1 variant, splice-isoform, and APOL3 interaction studies. This guide translates recent APOL1 mechanistic findings into practical assay design, transfection controls, and interpretation strategies.
-
Protease Inhibitor Cocktail for Lipid Droplet Assays
2026-08-11
Protect DFCP1–ATGL complexes and other labile proteins during starvation, lipid droplet, cell lysate, and tissue extract workflows. This EDTA-containing, water-soluble protease inhibitor mixture adds broad-spectrum protection while requiring deliberate compatibility checks for IMAC, kinase, and metal-dependent assays.
-
SCH772984 HCl: ERK Control of TERT
2026-08-10
Explore how SCH772984 HCl, a potent ERK1/2 inhibitor, can connect MAPK pathway activity with TERT transcription and chromatin state. This article translates recent stem-cell findings into practical assay decisions for cancer signaling and resistance research.
-
KPT330 and Cas9 Precision: mRNA Export Control
2026-08-09
The reference study identifies selective inhibitors of nuclear export, particularly KPT330, as indirect regulators of Cas9, base-editor, and prime-editor activity. By restricting nuclear export of Cas9 mRNA rather than binding the Cas9 protein directly, this strategy provides a route to reduce excessive editing activity and improve specificity in human cells.
-
BAY-826: A Causal Map for Retinal Signaling
2026-08-08
BAY-826 is a potent small molecule inhibitor for dissecting Ang–Tie-2 signaling, Müller cell communication, and retinal neuron survival. This article focuses on causal assay design, pathway attribution, and practical controls rather than repeating a conventional product overview.
-
Prostaglandin E2: From Metabolomics to Assay Design
2026-08-07
Prostaglandin E2 links receptor-level perturbation with tissue-resolved metabolomics and systems pharmacology. This guide shows how PGE2 can improve assay decisions without overstating what complex cardiovascular disease models prove.
-
Redefining CRISPR Precision with Advanced Cas9 mRNA Engineer
2026-08-07
This thought-leadership article presents a mechanistic and strategic perspective on leveraging advanced mRNA engineering for CRISPR-Cas9 genome editing. We integrate biological rationale, recent breakthroughs in mRNA export modulation, and practical workflow guidance, focusing on the unique properties of EZ Cap™ Cas9 mRNA (m1Ψ). By connecting recent peer-reviewed findings with translational research needs, we deliver actionable insights for maximizing editing precision, minimizing off-target effects, and accelerating clinical translation.
-
Dimethyloxalylglycine (DMOG): Protocols and Technical Guidan
2026-08-06
Dimethyloxalylglycine (DMOG) is designed for controlled, reversible stabilization of hypoxia-inducible factors, allowing researchers to mimic hypoxic signaling in vitro and in vivo models. It should only be used in research workflows evaluating oxygen sensing, hypoxia pathways, and inflammation—not for diagnostic or clinical purposes.